What is the P21 peptide?

The short answer

The P21 peptide is P021, a small synthetic compound modelled on part of ciliary neurotrophic factor, a protein that supports nerve cells. It is four amino acids plus a glycine carrying an adamantane group, a bulky hydrocarbon cage. It was designed and has been studied almost exclusively by one laboratory in New York, mainly in mouse models of Alzheimer's disease and related conditions.

That concentration is the single most important thing to understand about it.

Not the p21 you may have found first

Search the scientific literature for "p21" and most results concern a different molecule. p21, also called p21Cip1 or WAF1, is a protein encoded by the CDKN1A gene that inhibits cyclin-dependent kinases and helps halt the cell cycle. It was described in 1993, including by Harper, Elledge and colleagues. There is also a Ras protein historically called p21.

None of these is related to P021. The overlap is purely a naming accident, made worse because the compound's first paper used the spelling P21.

From a growth factor to a four-residue fragment

CNTF has been studied for its support of neurons, but as a full-length protein it is large and does not readily cross into the brain. Khalid Iqbal's group at the New York State Institute for Basic Research in Developmental Disabilities set out to find a small piece that kept some of its activity.

According to the group's own 2016 review, they first identified an 11-residue region of human CNTF, residues 146 to 156, and made it as Peptide 6. They then narrowed the active region to four residues, Asp-Gly-Gly-Leu, and added a glycine carrying an adamantane group at the C-terminus to improve its ability to cross the blood-brain barrier. The result, published by Li and colleagues in 2010, was the compound named P21 and later P021.

The adamantane cap follows a design idea seen in other research compounds: a bulky, fat-soluble group that makes a short peptide more lipophilic. Our guide to dihexa describes a similar approach applied to an angiotensin fragment.

What the studies examined

The published work falls into a few groups, all in animals or cultured cells:

• Normal adult mice. The 2010 paper reported improved performance in learning and memory tasks and increased formation and maturation of new neurons in the dentate gyrus, part of the hippocampus.
• Aged rats. Bolognin and colleagues reported in 2014 that long-term exposure reduced age-related decline in learning tasks in rats aged 22 to 24 months, with increased BDNF expression and reduced neurogenesis deficits.
• Alzheimer's disease models. Kazim and colleagues reported in 2014 that P021 reduced abnormal tau phosphorylation in a triple-transgenic mouse model, with a smaller effect on amyloid: lower soluble amyloid-beta and a non-significant trend in plaque load. They proposed a mechanism through increased BDNF and reduced GSK-3 beta activity.
• Down syndrome model. A 2017 study in Ts65Dn mice reported that exposure from before birth into early life rescued developmental delay in pups and memory deficits in adulthood.
• CDKL5 deficiency. A 2024 study led from the University of Bologna found that P021 corrected several deficits in cultured human neuronal cells lacking CDKL5, but in mice lacking the gene it did not raise BDNF or improve brain structure, and behavioural benefit was limited.

The last result is worth noticing: it is one of only two studies we found that were led from outside the originating laboratory, and its in-vivo result was largely negative. The other, a 2026 brain-imaging study from the Medical University of South Carolina, also lists Iqbal as an author, and its competing-interests statement records a shared patent application on P021.

How narrow the evidence base is

Every primary P021 study we found on PubMed lists Khalid Iqbal as an author, including the two led from other universities. The Bologna paper's competing-interests statement discloses that he co-founded and is chief scientific officer of Phanes Biotech, holds patents on the composition and use of P021, and is developing it as a drug candidate for Alzheimer's disease and related disorders.

Nothing about that is improper; it is normal for a compound's inventors to study it first. But it means the findings have not been independently replicated by groups with no connection to the developers, and the work is in rodents and cell cultures. We found no human study registered on ClinicalTrials.gov. Rodent memory tasks and tissue markers are useful research readouts, but they are a long way from showing anything in people. Our guide to Semax describes another neuro-research compound whose literature is concentrated in a single programme.

Where MY PEPTIDES stands

We do not stock P021, hold no certificate for it, and this page is not an offer to supply it. For what we do sell, see the catalogue; for how to judge a research compound's documentation in general, see what research peptides are.

The bottom line

The P21 peptide is P021: four residues of ciliary neurotrophic factor capped with an adamantane-bearing glycine, designed in one New York laboratory to cross into the brain. It has been reported to affect neurogenesis, BDNF and tau markers in mice and rats, almost entirely by that laboratory, whose senior scientist is developing it commercially. It is unrelated to the p21 cell-cycle protein, has no human trial on record, and we do not supply it.

All compounds referenced on this site are discussed strictly in the context of in-vitro laboratory research. Nothing here is a medicine, a supplement or a therapeutic product, nothing here describes administration to humans or animals, and this guide is general information rather than medical, legal or research advice.